Talk:Amitriptyline
| Amitriptyline | |||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
 |
|||||||||||||||||||||||||||||||
| Chemical Nomenclature | |||||||||||||||||||||||||||||||
| Common names | Amitriptyline, Elavil, Vanatrip | ||||||||||||||||||||||||||||||
| Systematic name | (5α,6α)-7,8-Didehydro-4,5-epoxy-3-methoxy-17-methylmorphinan-6-ol | ||||||||||||||||||||||||||||||
| Class Membership | |||||||||||||||||||||||||||||||
| Psychoactive class | Antidepressant | ||||||||||||||||||||||||||||||
| Chemical class | Tricyclic antidepressants | ||||||||||||||||||||||||||||||
| Routes of Administration | |||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||
| Interactions | |||||||||||||||||||||||||||||||
Amitriptyline (trade name Elavil or Vanatrip) is a tricyclic antidepressant drug used to treat depression, chronic neuropathic pain and migraines. It was first developed by the American pharmaceutical company Merck in the late 1950s. Amitriptyline is on the WHO Model List of Essential Medicines, the most important medications needed in a basic health system. Due to the frequency and prominence of side effects, amitriptyline is generally considered a second-line medication.
History and culture
In the 1950s the pharmaceutical company Merck proposed clinical trials to use amitriptyline as a treatment for schizophrenia, researcher Frank Ayd instead suggested that the medication be used as an antidepressant. Ayd treated 130 patients with amitriptyline and reported that it had similar qualities to imipramine, the first and only tricyclic antidepressant. It was approved for treatment of depression by the FDA in 1961.
Pharmaceutical companies Roche and Lundbeck were also able to create patents on the drug thanks to a quirk of the patent law in the EU at the time allowing patents only on the chemical synthesis, but not on the drug itself.
The drug quickly surpassed its predecessor, imipramine, because of its stronger anxiolytic effect and a campaign by the Merck company, raising awareness of depression as a clinical issue. Between 1998 and 2017 amitryptaline was the most prescribed antidepressant for 11-17 year olds in England
Chemistry
Pharmacology
Subjective Effects
Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.
It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.
Toxicity and harm potential
See also
External links